Results 31 to 40 of about 659,528 (297)

Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia. [PDF]

PLoS Medicine, 2005
Pneumonia remains the leading cause of death in young children. The poor specificity of chest radiographs (CXRs) to diagnose pneumococcal pneumonia may underestimate the efficacy of pneumococcal conjugate vaccine in preventing pneumococcal pneumonia.The ...
Shabir A Madhi, Jayvant R Heera, Locadiah Kuwanda, Keith P Klugman   +3 more
doaj   +1 more source

Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study

PLoS Medicine, 2020
Background Vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23) is available in the United Kingdom to adults aged 65 years or older and those in defined clinical risk groups.
H. Lawrence, H. Pick, V. Baskaran, P. Daniel, C. Rodrigo, D. Ashton, Rochelle C Edwards-Pritchard, C. Sheppard, S. Eletu, D. Litt, N. Fry, Samuel Rose, C. Trotter, T. McKeever, W. Lim   +14 more
semanticscholar   +1 more source

The impact of pharmacist-led educational intervention on pneumococcal vaccine awareness and acceptance among elderly in Jordan

Human Vaccines & Immunotherapeutics, 2021
Limited data exist regarding pneumococcal vaccination coverage among the elderly in Middle Eastern countries including Jordan. The pharmacists’ role in improving vaccine acceptance has become increasingly evident.
Eman Y. Abu-rish, Noor A. Barakat
doaj   +1 more source

Recent progress in pneumococcal protein vaccines

Frontiers in Immunology, 2023
Pneumococcal infections continue to pose a significant global health concern, necessitating the development of effective vaccines. Despite the progress shown by pneumococcal polysaccharide and conjugate vaccines, their limited coverage and the emergence ...
Sha Li, Hangeri Liang, Shui-Hao Zhao, Xiao-Yan Yang, Zhong Guo   +4 more
doaj   +1 more source

Monitoring the introduction of pneumococcal conjugate vaccines into West Africa: design and implementation of a population-based surveillance system. [PDF]

, 2012
Routine use of pneumococcal conjugate vaccines (PCVs) in developing countries is expected to lead to a significant reduction in childhood deaths. However, PCVs have been associated with replacement disease with non-vaccine serotypes.
Adegbola, Richard A, Akinsola, Bolanle, Baldeh, Ignatius, Greenwood, Brian M, Hill, Philip C, Howie, Stephen RC, Ikumapayi, Usman N, Jasseh, Momodou, Knoll, Maria Deloria, Lee, Ellen, Levine, Orin S, Mackenzie, Grant A, Plumb, Ian D, Saha, Debasish, Sambou, Sana, Touray, Kebba, Uchendu, Uchendu, Usuf, Effua, Wattiaux, Andre   +18 more
core   +2 more sources

Impact of Pneumococcal Conjugate Vaccines on Pneumonia Hospitalizations in High- and Low-Income Subpopulations in Brazil. [PDF]

, 2017
BackgroundPneumococcal conjugate vaccines (PCVs) are being used worldwide. A key question is whether the impact of PCVs on pneumonia is similar in low- and high-income populations.
Kürüm, Esra, Lustig, Roger, Schuck-Paim, Cynthia, Shioda, Kayoko, Simonsen, Lone, Taylor, Robert J, Warren, Joshua L, Weinberger, Daniel M   +7 more
core   +2 more sources

Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006–18: prospective observational time-series and case-control studies

Lancet Global Health, 2020
Summary Background The population impact of pneumococcal conjugate vaccines (PCVs) depends on direct and indirect protection. Following Malawi's introduction of the 13-valent PCV (PCV13) in 2011, we examined its impact on vaccine and non-vaccine serotype
N. Bar-Zeev, T. Swarthout, D. Everett, M. Alaerts, J. Msefula, C. Brown, Sithembile Bilima, J. Mallewa, Carina King, A. von Gottberg, J. Verani, C. Whitney, C. Mwansambo, S. Gordon, N. Cunliffe, N. French, R. Heyderman   +16 more
semanticscholar   +1 more source

Invasive pneumococcal infection due to serotype 15A after the pneumococcal conjugate vaccine implementation in Turkey

Human Vaccines & Immunotherapeutics, 2017
Invasive pneumococcal infections among children are a serious public health problem in many countries, including Turkey. Pneumococcal conjugate vaccine has been included in Turkey's National Immunization Programme since 2009.
Ayşe Büyükcam, Hüseyin Güdücüoğlu, Kamuran Karaman, Venhar Gürbüz, Emil Aliyev, Ateş Kara, Mehmet Ceyhan   +6 more
doaj   +1 more source

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly [PDF]

, 2018
Background: Pneumonia is one of the leading causes of mortality and has a high burden in morbidity. In Portugal, 7-valent pneumococcal conjugated vaccine (PCV) was used since 2001 and PCV10/13 since 2009, being the last introduced into the National ...
Froes, Filipe, Gonçalves, Paulo, Gómez, Verónica, Kislaya, Irina, Nunes, Baltazar, Rodrigues, Ana Paula, Sousa-Uva, Mafalda   +6 more
core   +2 more sources

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices

MMWR. Morbidity and mortality weekly report, 2019
Two pneumococcal vaccines are currently licensed for use in adults in the United States: a 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Pfizer, Inc.]) and a 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax 23, Merck and Co.
Almea M Matanock, Grace M. Lee, R. Gierke, Miwako Kobayashi, A. Leidner, T. Pilishvili   +5 more
semanticscholar   +1 more source